Effect of hyperimmune bovine milk & colostrum in the healing process of COVID-19 patients

Comparison of the Effectiveness of COVID-19 specific antibody in hyperimmune bovine milk & colostrum with ordinary bovine milk & colostrum in improving clinical symptoms and laboratory parameters and outcomes of patients with COVID-19 admitted to Hospital

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200927048849N2

Enrollment

Registered

2021-01-06

Start date

2020-11-27

Completion date

Unknown

Last updated

2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19. COVID-19, virus identified

Interventions

Intervention 1: Intervention group: Intervention group: Noncritical hospitalized COVID- 19 infected patients. After explaining the study and obtaining consent form the intervention group will be given

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Infected patients of COVID-19 based on positive PCR or HRCT result compatible with disease Hospitalization of patient in hospital With oxygen via nasal cannula 93%=O2 Sat Age >18years old Filling and signing of consent form Allowing the patient to consume food orally

Exclusion criteria

Exclusion criteria: Patients with immunodeficiency based on biography Patients with Lactose intolerance based on biography Uncontrollable vomit

Design outcomes

Primary

Measure	Time frame
Hospital mortality rate. Timepoint: Daily from intervention. Method of measurement: Physician approval.;Mortality rate during 28 days after the beginning of disease. Timepoint: Daily from intervention. Method of measurement: Physician approval during admission and via tell contact after discharge.;Admission rate of patient in ICU (based on hospital protocols). Timepoint: Daily from intervention. Method of measurement: Refer to the patient's file.;Days that patient needs to be hospitalized. Timepoint: Daily from intervention. Method of measurement: Refer to the patient's file.	—

Measure

Time frame

Hospital mortality rate. Timepoint: Daily from intervention. Method of measurement: Physician approval.;Mortality rate during 28 days after the beginning of disease. Timepoint: Daily from intervention. Method of measurement: Physician approval during admission and via tell contact after discharge.;Admission rate of patient in ICU (based on hospital protocols). Timepoint: Daily from intervention. Method of measurement: Refer to the patient's file.;Days that patient needs to be hospitalized. Timepoint: Daily from intervention. Method of measurement: Refer to the patient's file.

—

Secondary

Measure	Time frame
O2 Saturation. Timepoint: Measuring in the first day and days 3 and 5 or in the day of discharge. Method of measurement: Pulseoximetry.;Improvement rate of clinical symptoms such as dyspnea and fever. Timepoint: Measuring in the first day and days of 3 and 5 or in the day of discharge. Method of measurement: Data gathering sheet.;Erythrocytes sedimentation rate. Timepoint: Measuring in the first day and days of 3 and 5 or in the day of discharge. Method of measurement: Blood test via wester green method.;C-Reactive protein. Timepoint: Measuring in the first day and days of 3 and 5 or in the day of discharge. Method of measurement: Blood test.;Lymphocytopenia. Timepoint: Measuring in the first day and days of 3 and 5 or in the day of discharge. Method of measurement: Blood test (CBC/Diff).	—

Measure

Time frame

O2 Saturation. Timepoint: Measuring in the first day and days 3 and 5 or in the day of discharge. Method of measurement: Pulseoximetry.;Improvement rate of clinical symptoms such as dyspnea and fever. Timepoint: Measuring in the first day and days of 3 and 5 or in the day of discharge. Method of measurement: Data gathering sheet.;Erythrocytes sedimentation rate. Timepoint: Measuring in the first day and days of 3 and 5 or in the day of discharge. Method of measurement: Blood test via wester green method.;C-Reactive protein. Timepoint: Measuring in the first day and days of 3 and 5 or in the day of discharge. Method of measurement: Blood test.;Lymphocytopenia. Timepoint: Measuring in the first day and days of 3 and 5 or in the day of discharge. Method of measurement: Blood test (CBC/Diff).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSomayeh Sadeghi

Esfahan University of Medical Sciences

S.sadeghi117917@gmail.com+98 31 3261 6331

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026